c erbb Search Results


monoclonal anti egfr antibody a 10  (MedChemExpress)
93
MedChemExpress monoclonal anti egfr antibody a 10
Monoclonal Anti Egfr Antibody A 10, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal anti egfr antibody a 10/product/MedChemExpress
Average 93 stars, based on 1 article reviews
monoclonal anti egfr antibody a 10 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
05cbs  (Carna Inc)
95
Carna Inc 05cbs
05cbs, supplied by Carna Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/05cbs/product/Carna Inc
Average 95 stars, based on 1 article reviews
05cbs - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
anti egfr  (Proteintech)
96
Proteintech anti egfr
Anti Egfr, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti egfr/product/Proteintech
Average 96 stars, based on 1 article reviews
anti egfr - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
erbb2  (Proteintech)
95
Proteintech erbb2
Erbb2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/erbb2/product/Proteintech
Average 95 stars, based on 1 article reviews
erbb2 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
erbb3  (Proteintech)
93
Proteintech erbb3
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Erbb3, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/erbb3/product/Proteintech
Average 93 stars, based on 1 article reviews
erbb3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
antibody anti egfr  (Boster Bio)
93
Boster Bio antibody anti egfr
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Antibody Anti Egfr, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody anti egfr/product/Boster Bio
Average 93 stars, based on 1 article reviews
antibody anti egfr - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
primary antibodies against egfr  (Proteintech)
94
Proteintech primary antibodies against egfr
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Primary Antibodies Against Egfr, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against egfr/product/Proteintech
Average 94 stars, based on 1 article reviews
primary antibodies against egfr - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
egfr 22542  (Proteintech)
92
Proteintech egfr 22542
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Egfr 22542, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfr 22542/product/Proteintech
Average 92 stars, based on 1 article reviews
egfr 22542 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
mouse polyclonal antibody against epidermal growth factor egf receptor  (Boster Bio)
91
Boster Bio mouse polyclonal antibody against epidermal growth factor egf receptor
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Mouse Polyclonal Antibody Against Epidermal Growth Factor Egf Receptor, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse polyclonal antibody against epidermal growth factor egf receptor/product/Boster Bio
Average 91 stars, based on 1 article reviews
mouse polyclonal antibody against epidermal growth factor egf receptor - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
pcmv6 vector  (OriGene)
93
OriGene pcmv6 vector
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Pcmv6 Vector, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcmv6 vector/product/OriGene
Average 93 stars, based on 1 article reviews
pcmv6 vector - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
bsm 33051m a647  (Bioss)
94
Bioss bsm 33051m a647
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Bsm 33051m A647, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bsm 33051m a647/product/Bioss
Average 94 stars, based on 1 article reviews
bsm 33051m a647 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
egfr  (MedChemExpress)
93
MedChemExpress egfr
Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of <t>ERBB3.</t> GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.
Egfr, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfr/product/MedChemExpress
Average 93 stars, based on 1 article reviews
egfr - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of ERBB3. GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.

Journal: Oncotarget

Article Title: Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer.

doi: 10.18632/oncotarget.14968

Figure Lengend Snippet: Figure 1: ERBB2 as target of miR-3622-5p. A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of ERBB3. GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3’-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3’-UTR (ERBB2-3’UTR-WT) or the fragment of ERBB2 3’-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3’-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3’UTR-WT or ERBB2-3’-UTR-del in SK-BR-3 cells.

Article Snippet: The primary antibody for ERBB3 was purchased from Proteintech Wuhan Sanying (Wuhan, China).

Techniques: Western Blot, Over Expression, Expressing, Control, Sequencing, Luciferase, Activity Assay, Cotransfection, Binding Assay, Transfection